Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

Cancer Science

Volumn 101, Issue 9, 2010, Pages 2005-2010

  Yin, Cameron C ^a   Cortes, Jorge ^a   Galbincea, John ^a   Reddy, Neelima ^a   Breeden, Megan ^a   Jabbour, Elias ^a   Luthra, Rajyalakshmi ^a   Jones, Dan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL 1 PROTEIN; BCR ABL PROTEIN; IMATINIB; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SUBSTITUTION; CLONE CELLS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955949422     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01627.x     Document Type: Article

References (15)

1. Cortes J, Jabbour E, Kantarjian H. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007, 110:4005-11.
2. Soverini S, Colarossi S, Gnani A. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12:7374-9.
3. Jabbour E, Kantarjian H, Jones D. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-73.
4. Lahaye T, Riehm B, Berger U. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005, 103:1659-69.
5. Al-Ali HK, Heinrich MC, Lange T. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004, 5:55-60.
6. Branford S, Rudzki Z, Walsh S. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-83.
7. Shah NP, Skaggs BJ, Branford S. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007, 117:2562-9.
8. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. Expert Opin Investig Drugs 2007, 16:679-87.
9. Jones D, Thomas D, Yin C. Kinase domain point mutations in Ph chromosome-positive acute lymphoblastic leukemia (ALL) emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008, 113:985-94.
10. Cortes J, Talpaz M, O'Brien S. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005, 11:3425-32.
11. Luthra R, Medeiros LJ. TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Methods Mol Biol 2006, 335:135-45.
12. Khorashad JS, Milojkovic D, Mehta P. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008, 111:2378-81.
13. Khorashad JS, Anand M, Marin D. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006, 20:658-63.
14. Giles FJ, Cortes J, Jones D. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-2.
15. de Lavallade H, Khorashad JS, Davis HP. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007, 110:2779-80.